According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
Separately, StockNews.com downgraded Cellectis from a hold rating to a sell rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $18.88.
Cellectis (NASDAQ:CLLS – Get Rating) last released its earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.50. The company had revenue of $13.66 million for the quarter, compared to analyst estimates of $12.30 million. Cellectis had a negative net margin of 170.26% and a negative return on equity of 41.88%. During the same period in the prior year, the business earned ($0.95) EPS. Analysts expect that Cellectis will post -2.37 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. OLD Mission Capital LLC purchased a new stake in Cellectis during the 3rd quarter worth about $253,000. Deutsche Bank AG purchased a new stake in Cellectis during the third quarter worth approximately $42,000. BlackRock Inc. boosted its holdings in Cellectis by 5.9% in the third quarter. BlackRock Inc. now owns 312,256 shares of the biotechnology company’s stock valued at $3,937,000 after purchasing an additional 17,387 shares in the last quarter. KBC Group NV increased its stake in Cellectis by 29.1% in the third quarter. KBC Group NV now owns 163,447 shares of the biotechnology company’s stock valued at $2,061,000 after purchasing an additional 36,862 shares during the last quarter. Finally, US Bancorp DE increased its stake in Cellectis by 94.0% in the third quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,130 shares during the last quarter. Hedge funds and other institutional investors own 40.55% of the company’s stock.
Cellectis Company Profile (Get Rating)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.